Detection of novel Plasmodium falciparum coronin gene mutations in a recrudescent ACT-treated patient in South-Western Nigeria

Introduction

The emergence and spread of resistance to antimalarial drugs in Plasmodium spp. and resistance to insecticides in the mosquito vectors are the two leading limitations to the control of malaria (WHO, 2023). In sub-Sahara Africa (sSA), the first-line treatment for the most common malaria parasite, Plasmodium falciparum, is artemisinin-based combination therapies (ACTs), which include artemether-lumefantrine (AL), artesunate-amodiaquine (AS-AQ) and dihydroartemisinin-piperaquine (DHA-PPQ) (Yobi et al., 2020). Cases of clinical failure of these combination drugs or their components have been reported in Africa, sparking fears of reduced efficacy or outright resistance. In the historical paths to resistance, failure of ACTs in Asia has been linked to mutations in the P. falciparum genome, with variants in the Kelch13 gene (Pfk13) associated with resistance to artemisinin derivatives (White, 2004; Taylor et al., 2018; Conrad and Rosenthal, 2019; WWARN, 2019; Ajibaye et al., 2020; Ikegbunam et al., 2021). Meanwhile, resistance to partner drugs is well known and associated with mutations in several genes, including, chloroquine resistance transporter (Pfcrt codon 72 to 76, haplotype SVMNT), multidrug resistance protein-1(Pfmdr1: N86F, N86Y, Y184F, S1034C) for amodiaquine resistance, and multiple copies of plasmepsin genes (Pfpm2) for piperaquine resistance (Yobi et al., 2020). Beyond these, single nucleotide variants in the P. falciparum actin-binding protein- Pfcoronin (G50E, R100K, and E107V) and Pfap2-mu have been implicated in increased in vitro tolerance to artemisinin, linked to kelch-13-independent mechanisms (Demas et al., 2018; Henrici et al., 2019; Stokes et al., 2021). The frequency of artemisinin resistance-associated variants in natural malaria parasite infections in Africa remains low and their roles in clinical response to ACTs remain unclear. As other P. falciparum genetic factors may be mediating kelch13-independent artemisinin tolerance mechanisms in Africa, improved continuous genetic surveillance and functional studies will be useful in effectively assessing and strategizing treatment regimens to prolong the effectiveness of current malaria treatments. Additionally, several non-Asian type Pfkelch-13 variants associated with decreased sensitivity to artemisinin are reported across Africa, though in low frequencies (Stokes et al., 2021). With continuous use of ACTs for first-line treatment and consideration for its use for chemopreventive mass interventions, these common African variants of Pfkelch-13 could be selected to become dominant as observed in Rwanda and Uganda (Sharma et al., 2020). Their presence and spread across Africa will severely impede the efficacy of artemisinin-based treatments. Currently, there is only one report for Pfcoronin involvement in antimalarial drug resistance, but this report is an in vitro study (Demas et al., 2018; Henrici et al., 2019). Hence, whether Pfcoronin SNPs may be associated with parasite ART tolerance in vivo is not known.

Further research and investigation are necessary to ascertain the relationship between Pfcoronin mutations and reduced ART susceptibility in clinical setup.

Pfcoronin is a WD40-propeller domain protein family member that shares the β-propeller motif with PfKelch13 protein (Adams et al., 2000). In eukaryotes, Kelch and Coronin proteins have distinct functions, some Kelch domain-containing proteins are also actin-binding proteins, a function typical of Coronin proteins. Only one single-copy of coronin gene is encoded by the genomes of unicellular pathogens, including P. falciparum (Xavier et al., 2008). The encoded protein generally binds F-actin and plays significant roles in proliferation, locomotion, and phagocytosis in eukaryotes (Xavier et al., 2008).

In addition to routine in vivo monitoring of antimalarial efficacy, the WHO recently released a strategy for genomic surveillance of infectious pathogens, emphasizing its contribution to disease surveillance and intervention policy (WHO, 2022). For the major malaria parasite, P. falciparum, several molecular surveillance approaches for drug resistance analysis based on microsatellites and SNP barcodes as well as highly diverse surface antigens have been in existence. The Genomes of several thousand isolates are now also publicly available, allowing for mining more markers, including those related to resistance to previous and current drugs. These combined, allow for temporal and spatial monitoring of the effect of interventions on diversity and the evolution of important phenotypes such as drug and vaccine resistance. The increasing pressure from interventions for malaria elimination in high transmission areas such as Nigeria, and consequent discontinuity in spatial flow of infections as populations dwindle may result in sub-structuring with selection and establishment of emerging drug resistance in response to sustained drug use, and reduced recombination (Auburn et al., 2011).

Several molecular diagnostic techniques have been validated, the Taqman var acidic terminal sequence (varATS) -based real-time PCR method is ultra-sensitive, very reliable, but relatively costly. Especially for resource limited settings. Hence, the need for cheaper, acceptably sensitive methods adaptable in such settings. Malaria transmission in Nigeria is substantially heterogeneous with seasonality observed in the North and perennial transmission in the South (Snounou and Beck, 2002; Selvaraj et al., 2018; Oladipo et al., 2022). Endemicity shows graduation throughout the country. Despite the considerable increase in malaria control efforts by the National Malaria Elimination Programme (NMEP), Nigeria remains one of the countries with the highest incidence of malaria morbidity and mortality (WHO, 2023). Various ACTs are easy to access for treatment across the country, while Sulphadoxine-Pyrimethamine and Amodiaquine are used for seasonal malaria chemoprevention in the northern Sahel regions. This may potentiate emergence of drug tolerance by the circulating drug resistant P. falciparum strains in the country. This study surveyed isolates from a therapeutic efficacy study in Lagos (Southwest Nigeria) for single nucleotide polymorphisms (SNPs) in P. falciparum antimalarial resistance markers, including Pfcoronin, which is associated with reduced in vitro sensitivity to artemisinin (Demas et al., 2018). The genetic diversity of this P. falciparum population was also evaluated.

Methods

Study design and ethical considerations

This antimalarial drug surveillance study was a one-arm prospective evaluation of clinical and parasitological responses to observed treatment for uncomplicated malaria following the guidelines of the WHO Global Malaria Programme updated in 2021 (http://www.who.int/malaria/areas/drug_resistance/en/).

Participants with uncomplicated malaria who met the study inclusion criteria were enrolled, treated on site with Artemether-lumefantrine (AL) and monitored for 28 days. The follow-up consisted of a fixed schedule of check-up visits and corresponding clinical and parasitological examinations. On the basis of the results of these assessments, the patients were classified as having therapeutic failure (early or late) or an adequate response. The proportion of patients experiencing therapeutic failure during the follow-up period was used to describe AL efficacy in the population. Molecular analysis was used to distinguish between recrudescence and episodes of reinfection.

This study was carried out at Ijede General hospital (IJGH), Ijede, Ikorodu, Lagos, South-West, Nigeria. Ijede is a rural settlement, located along the Lagos Lagoon on Latitude 6^° 34’ 00’’N and Longitude 3^° 35’ 18’’ (Figure 1); bordering Ogun State. The community has an estimated population of 535,619 inhabitants.

Figure 1

Figure 1 Map of study site. Top Right: Map of Nigeria showing the location of Lagos State; Down Right: Zoomed-Map of Lagos showing Location of Ijede; Left: Map of Ijede showing the location of Ijede General Hospital (IJGH). Pink: Study area including the Health facility; Light blue: Areas bordering water bodies around the study site.

Only participants who consented were included in the study after they or parents or guardians of those who were children gave informed consent. Ethical approval for the study was obtained from the Institutional Ethics Review Board of the Nigerian Institute of Medical Research (NIMR IRB No: IRB/21/030). All the research participants gave written informed consent, guardian/parental consent and/or assent (for participants aged 7- 11 years).

Participants in this study were primarily recruited for in vivo therapeutic efficacy study (TES) of Artemether-Lumefantrine (AL) conducted between July and September 2019. Inclusion criteria included, (1) being aged ≥ 12 months to <70 years (for ease of follow-up), (2) symptoms suggestive of uncomplicated malaria including an axillary temperature of ≥ 37.5 °C or a history of fever in the last 24 hours preceding presentation, (3) confirmed microscopically, P. falciparum mono-infection (Day 0) with asexual parasite counts ≥ 2,000/μl. Individuals presenting at this facility were initially screened with histidine-rich protein 2-based malaria rapid diagnostic test kits (HRP2-mRDTs). All test results were simultaneously confirmed by microscopy and later on with molecular methods at all time-points. Giemsa-stained thick blood films were read with 200 white blood cells (WBCs) counted by light microscopy. Parasite density (asexual parasites per microlitre of blood), was calculated as number of asexual parasites divided by the number of WBCs counted (200) and then multiplying it by an assumed WBC number (8000 cells/L). Individuals with severe malaria, malnutrition, serious underlying diseases (renal, cardiac, or hepatic diseases), severe malnutrition, severe danger signs, or signs of severe malaria, and known allergies to AL were excluded from the study. Individuals with other relatively common febrile conditions like otitis media, tonsillitis, measles and abscesses were also excluded. Pregnant (as determined by the human chorionic gonadotropin test) and lactating women were excluded. Participants received AL (Coartem) (Novartis, Switzerland) according to the Nigeria Federal Ministry of Health (FMoH) treatment guideline and directly observed closely. For adults (at least 35 kg), 4 tablets taken orally as a single initial dose, followed by 4 tablets after 8 hours, and then 4 tablets twice a day (morning and evening) for the following 2 days, making a total course of 24 tablets. For children (5 to less than 15 kg), 1 tablet taken orally as a single initial dose, followed by 1 tablet after 8 hours, and then 1 tablet twice a day (morning and evening) for the following 2 days (total course of 6 tablets); Weight 15 to less than 25 kg, 2 tablets taken orally as a single initial dose, followed by 2 tablets after 8 hours, and then 2 tablets twice a day (morning and evening) for the following 2 days, a total course of 12 tablets; Weight 25 to less than 35 kg, 3 tablets orally as a single initial dose, followed by 3 tablets after 8 hours, and then 3 tablets twice a day (morning and evening) for the following 2 days for a total course of 18 tablets.

Participants were followed up on days 1 to 3 and then on days 7, 14, 21 and 28 for parasite clearance. Antimalarial drugs were administered as directly observed therapy (DOT), after normal meal, while the participants visited the health facility. Participants were treated with Dihydroartemisinin-piperaquine in cases where infection did not resolve after AL administration. Early Treatment Failure (ETF) was taken as persistence of parasitaemia up till day 3 with axillary temperature ≥ 37.5°C; Late Parasitological Failure (LPF) was parasitaemia on any day between day 7 and day 28 with axillary temperature ≥ 37.5°C; Late Clinical Failure (LCF) was presence of danger signs or severe malaria or parasitaemia with axillary temperature ≥37.5°C between day 4 and day 28, without having been previously classified as ETF while Adequate Clinical and Parasitological Response (ACPR) was taken as absence of parasitaemia on day 28, in patients who did not previously meet any of the criteria for ETF or LTF. Two WHO certified microscopists read the slides, and the third read any slide with differing microscopy readings to resolve discrepancies. A 3 mL venous blood sample was collected into ethylene diamine tetra-acetic acid (EDTA) coated vacutainer bottles (Becton Dickinson) at commencement of treatment and each time point during follow up. To prepare parasite isolates for genotyping, 2 mL of each sample was depleted of human leukocytes by filtering through cellulose columns (Tiwari et al., 2012; Venkatesan et al., 2012; Rutledge et al., 2017). Each blood sample was also spotted on Whatman 3 filter paper (Whatman International, England) for genomic DNA (gDNA) extraction and other molecular assays.

Molecular diagnosis of infection with malaria parasites

Genomic DNA from each sample was extracted with the Qiagen blood Mini kit (CAT 51306, Qiagen, Hilden, Germany), and quantified with NanoDrop One Instrument (Thermo Fisher Scientific™, Wilmington, USA) (Desjardins and Conklin, 2010). Following microscopic examination, infection with P. falciparum for each sample was confirmed with three described molecular diagnostic techniques targeting the 18S srRNA gene in conventional and real-time PCR; the highly sensitive variable Acidic terminal sequence (varATS) and Telomere Associated Repetitive sequence (TARE)-2 by real-time PCR (Hofmann et al., 2015). For real time assays, samples were negative when cycle time (Ct) was ≥ 40. For the coupled PCR, the 18S primary PCR product was used as template for the real-Time PCR (Rutledge et al., 2017). Primers were synthesized by Macrogen Inc, Seoul, Korea.

Molecular genotyping of primary and recurrent infections

Each sample classified as positive for P. falciparum was first genotyped by amplifying the gene of merozoite surface protein II (msp2). The msp2 fragment sizes were used to classify new infections from recrudescence in the pre- and post-treatment parasite isolates. Genotyping msp2 employs nested-PCR to amplify the block 3 of msp2 containing two allelic families (Snounou, 2002; Snounou and Beck, 2002; Hofmann et al., 2015). Band size variability of less than 18 bp was taken as identical msp2 alleles. To further determine P. falciparum genetic diversity and pairwise similarity between infections from different time-points and individuals, 12 unlinked multi-locus microsatellite markers were amplified using a heminested PCR as described previously (Anderson et al., 2006; Druml et al., 2006; Murray et al., 2016). The loci analyzed included Polyα (Chr4), TA81(Chr5), PfPk2 (Chr12), ARAII (Chr11), TA87 (Chr 6), PfG377 (Chr12), TA40 (Chr10), TA60 (Chr13) and TA109 (Chr 6). The final labeled (FAM, HEX or PET dyes) heminested PCR products were first visualized on 1.5% agarose gel and further analyzed by capillary electrophoresis on a SeqStudio™ Genetic Analyzer (Applied Biosystems™, Foster City, CA, USA) together with GeneScan™ 600 LIZ internal size standards (Applied Biosystems, Foster City, CA) and for normalization across runs. Allele length and peak height per locus and samples were scored using GeneMapper software (Thermo Fisher Scientific, Dartford, UK). Minor alleles were scored when the minor peaks were ≥ 25% the height of the predominant allele in the isolate with a relative fluorescence unit of at least 100. Fragments within ±7bp sizes were binned. Multiple infections were defined when any of the loci contained multiple alleles at any of the microsatellite loci genotyped. Multilocus genotype similarity was inferred for pairs of isolates with the same allele sizes across all loci.

Drug resistance marker genotyping

We employed the high-resolution melting (HRM) Assay panel which simultaneously detects SNPs in three P. falciparum genes (pfmdr, pfdhps and pfdhfr) that are associated with antimalarial drug resistance (Daniels et al., 2012). PCR reactions were carried out using the Type-it HRM PCR kit (Qiagen, Germany) according to manufacturers’ protocol. Briefly, the reaction contained 1× HRM PCR master mix, 0.7µM (1×) of primers (S2) from a 10× primer mix and 1 µL DNA (~1 ng/µL) in a total reaction volume of 10 µL. Amplification cycle was 95°C denaturation for 5 min, followed by 50 cycles of 95°C for 10 s and 55°C for 30 s and 72°C for 10 s with single acquisition, and then a pre-melt cycle of 1s at 65°C followed by continuous fluorescence data acquisition (10 acquisitions per second) at 95°C. Products were then cooled to 40°C till end of the amplification cycle.

Plasmodium falciparum Kelch-13 (Pfk13) and coronin (pfcoronin) sequencing

An 848 bp Pfkelch-13 gene fragment was amplified from each infected sample by nested-PCR using the following primer sets: pfk13-F: 5′-CGGAGTGACCAAATCTGGGA-3′ and pfk13-R: 5′-GGGAATCTGGTGGTAACAGC-3′ for the primary reactions and pfk13-F: 5′-GCCAAGCTGCCATTCATTTG-3′ and pfk13-R: 5′-GCCTTGTTGAAAGAAGCAGA-3′ for the nested reaction. Pfkelch-13 PCR cycling conditions for both primary and nested reactions included 5 minutes of initial denaturation at 95°C followed by 40 cycles of 30 s denaturation at 94°C, 90 s annealing at 60°C, 90 s extension at 72°C and a 10 minutes final extension at 72°C. All PCR reactions were carried out with 2 μL of DNA in a total volume of 25 μL containing 0.2 mM dNTPs, 2 mM MgCl₂, 1 μM of each primer, and 1 unit of PfuUltra II Fusion HS DNA polymerase (Agilent Technologies, Santa Clara, USA). For the pfcoronin, a 542 bp fragment was amplified with the following primers pfcoro-F: 5’-ATGGCAAGTTGAAGGGGGAG-3’ and pfcoro-F:5’-TTGTCTTCACCACCAAATCCA-3’ in a one-step PCR amplification. Cycling conditions for the amplification of the pfcoronin were 95°C initial denaturation for 5 min, 40 cycles of denaturation at 95°C for 30 s, annealing at 56°C for 45 s and extension at 68°C for 30 s, these were followed by final extension at 72°C for 7 min. All amplicons were resolved on 1% agarose gel with ethidium bromide staining. PCR amplicons for sequencing were purified with Genomic DNA Clean & Concentrator-10 DNA clean up kit (Zymo Research, Irvine, USA). The purified DNA was sequenced bi-directionally on SeqStudio automatic DNA sequencer (Applied Biosystems™, Foster City, USA) using the BigDye Terminator Cycle Sequencing Kits (Applied Biosystems™, Foster City, USA) according to manufacturer’s instructions with the PCR amplification primers. Samples were re-sequenced to confirm SNVs.

Statistical and population genetic analyses

Parametric demographic data generated from the study were analyzed using One-way ANOVA and Tukey for multiple comparison while non-parametric microsatellite data were analyzed using Kruskal-Wallis and Dunn’s multiple comparison and Mann-Whitney test. Test of statistical significance was set at < 0.05 and confidence interval at 95%.

The allele frequencies and number of alleles per locus were calculated using GENALEX 6 [26]. Allelic diversity for each of the microsatellite loci was calculated using the formula for expected heterozygosity H_E = [(n/n-1) (1-∑p²)], where n is the number of isolates analyzed and p represents the frequency of each different allele at a locus. H_E is the proportion of heterozygosity expected under random mating and pi is the allele frequency of the i-th allele. Differences between the allelic diversity (H_E of the two groups i.e. pre and post drug treatment groups) was assessed using Mann-Whitney test in GraphPad Prism 8 (GraphPad Software, Inc). H_E has a potential range from 0 (no allele diversity) to 1 (all sampled alleles are different).

Linkage Disequilibrium microsatellite loci expressed as the standardized index of association (I_A^S), was determined using the web-based interface, LIAN version 3.7 (Haubold and Hudson, 2000; Peakall and Smouse, 2006). I^S_A = (1/n – 1 ((V_D/(V_E) – 1), where n is the number of loci for which two individuals differ, V_E and V_D are the expected and observed variance, respectively. Values range from 0 (no loci in LD) to 1 (all loci in LD). The null hypothesis of complete linkage equilibrium (I_A^S = 0) was tested by Monte-Carlo simulations using 10,000 random permutations of the data (Kumar et al., 2016). This genetic phenomenon follows recurrent recombination between alleles at distinct loci in LIAN to compare the variance in the number of alleles shared between all pairs of genotypes with the variance expected under a random association hypothesis. We assessed the genetic relatedness between pre- and post-drug infection haplotypes by calculating pairwise allele sharing (P_AS). Specifically, P_AS was calculated as the number of alleles shared between two infection (pre- and post-) haplotypes divided by the number of microsatellite markers (i.e., 12). Multivariate analysis of similar alleles to determine genetic variance among isolates Pre- and Post-AL administration was done by Principal Component Analysis (PCA) using the libraries Tidy-verse, Broom, Cowplot and ggplot2 in R (http://CRAN.R-project.org/) based on microsatellite data.

For Pfkelch-13 and Pfcoronin sequence analysis, chromatograms were manually edited and aligned to create sample contigs using Bioedit software. Contigs were then aligned with CLUSTAL W in MEGA 6 (Haubold and Hudson, 2000; Anderson et al., 2006; Peakall and Smouse, 2006). Multiple sequence alignments were compared against reference sequences of Pfkelch-13 (PF3D7_1251200) and Pfcoronin 3D7 (PF3D7_125200) strains and plasmodium spp homologues retrieved from the GenBank. SNPs were called using Geneious Prime software 2021.1.1 and SNPServer (http://hornbill.cspp.latrobe.edu.au/snpdiscovery.html). The number of haplotypes were analyzed using DnaSP version 6.12.03. The distance between sequences was assessed using a neighbor-joining (NJ) tree from Kimura-2-parameter distance matrix in MEGA 6 (Saitou and Nei, 1987; Tamura et al., 2004; Kumar et al., 2016) The consensus distance tree was displayed and visualized as a dendrogram.

Structure-function effect analysis of SNPs

Delta Delta G (DDG), a metric for predicting how a single point mutation will affect protein stability, often referred to as ΔΔG, is the change in Gibbs free energy. To predict the effects of non-synonymous SNPs on the structure and function of the identified P. falciparum coronin, a web-based tool, PremPS (Chen et al., 2020), was used with conservation score from alignment of threading template.

The robustness was confirmed with Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/). The 3D structure of the wild-type protein was obtained from the Protein data bank (https://swissmodel.expasy.org/interactive/4avQwh/templates/). The structures of mutants were produced with Build Model module of FoldX (http://foldxsuite.crg.eu/) using wild-type protein structure as the templates. We analyzed functional and structural stability using the change in Gibbs free energy expressed as. Delta Delta G (ΔΔG) between wild type and mutant PfCoronin protein. ΔΔG measures the change in energy between the folded and unfolded states (ΔGfolding) and the change in ΔGfolding when a point mutation is present.

Results

We analyzed P. falciparum samples collected in a 28-day in vivo therapeutic efficacy studies (TES) wherein we comparatively applied 18S rRNA gene PCR, real-time PCR, var ATS and TARE-2 for parasite molecular detection. We investigated genetic polymorphisms on PfCoronin for samples showing ART tolerance. P. falciparum neutral microsatellite analysis here was used to confirm recrudescent infections for genetic analysis. A total of 52, out of the 58, microscopically-confirmed P. falciparum malaria-positive subjects were included in the in vivo follow-up TES. Five (8.62%) subjects did not meet the inclusion criteria while one (1.72%) was lost to follow-up at Day 7 (Figure 2). The median age of the participants was 5.5 years and malaria prevalence was 31.52% in the study site. A total of 7(13.46%) cases resolved as early therapeutic failure (ETF), Late Parasitological Failure (LPF) or late clinical failure (LCF) after ACT treatment (Table 1). These infections cleared following treatment with the rescue drug, Dihydroartemisinin-piperaquine. Two of the cases showed symptoms on Day 14, including isolate 7 (with parasitaemia on Day 14). Results from the different molecular detection assays were comparable, although the two methods targeting higher copy number genes were relatively more sensitive with lower Ct values (Figure 3). Conventional PCR (of Day 0 samples) showed 54 (93.1%) of the samples were positive, 55 (94.8%) by 18S Real-Time PCR, coupled-qPCR 57 (98.3%) varATS and TARE-2 confirmed all the 58 participants’ samples positive for P. falciparum. Detection was significantly (ANOVA, p=0.0001) higher on Day0 than any other timepoints analyzed across the methods (Figure 3A); and a statistically significantly higher detection before AL administration (mean=54.4, SD=3.1) than after AL administration (mean=7.2, SD=1.5), t(52), p=0.006 was observed across the real-time PCR analysis methods (Figure 3B).

Figure 2

Figure 2 Enrollment and treatment outcomes.

Table 1

Table 1 Follow-up analysis.

Figure 3

Figure 3 Molecular detection of P. falciparum in study samples before and after AL Administration (A) Molecular detection of P. falciparum infection One-way ANOVA was performed to compare the difference in parasite detection on DayO, Day3 and Day >3 across the methods. The analysis revealed that there was a statistically significant difference in mean detection between at least two timepoints (F(4, 8) = [9.385], p = 0.0001). Tukey’s HSD Test for multiple comparisons showed significant difference in detection between Day0 and Day3 (p = 0.024, 95% C.I. = [-14.48, -0.92]); between Day3 and Day >3 (p=0.0041) and between Day0 and Day>3 (p=0.0001); (B) Real-Time PCR confirmation of P. falciparum in participants samples (Pre- and Post-AL administration). Molecular detection of P. falciparum was done employing five different methods including the conventional 18S srRNA gene nested-PCR (conPCR) and real-time PCR (18S real-time PCR, coupled 18S conventional and real-time PCR, varATS and TARE-2 real-time PCR) using gDNA from samples Pre- and Post-AL administration, with normalization with negative control ct values. A t-test performed for comparison of the difference in parasite detection, before and after AL administration, by real-time PCR methods showed statistically significantly higher detection before AL administration (mean=54.4, SD=3.1) than after AL administration (mean=7.2, SD=1.5), t(52), p=0.006.

Genotypes of pre- and post-treatment infections

Results following msp2 genotyping and agarose gel electrophoresis analysis showed three of the seven samples displaying recurrence infections during in vivo follow-up TES as recrudescence (Isolates 2, 5 and 7) and four re-infection (Isolates 1, 3, 4, and 6) (Additional File, (S3)). Microsatellites analysis however, confirmed only one infection as recrudescence, identical in the twelve loci pre- and post-AL administration (Figures 4A–C). Pairwise allele sharing (PAS) between the pre- and post-treatment P. falciparum parasites for this isolate also showed a score of 0.92 (identical in ≥ 11 loci), and another isolate a score of 0.75 (identical in nine loci) (Figure 4A).

Figure 4

Figure 4 Parasite genotyping (A) Pairwise Allele Sharing between P. falciparum Pre- and Post-Treatment Infection Haplotypes; (B) Principal component analysis of the Isolates Pre- and Post-Treatment administration using similar P. falciparum neutral multilocus microsatellites; (C) Allele sizes of twelve multi-locus microsatellite markers from P. falciparum isolates showing ART tolerance in Nigeria. Plasmodium falciparum isolates were genotyped by analysis.

Genetic diversity in terms of expected heterozygosity (H_e), allelic diversity, calculated for each microsatellite locus in the isolates from the two groups (pre- and post-AL administration) revealed overall (H_e): 0.8363 +/- 0.0273 and 0.584 ± 0.408 pre- and post-AL administration respectively. There was no significant difference in the overall mean allelic diversity, He, (P = 0.19, Mann-Whitney test) in the pre- and post-treatment groups (Table 2).

Table 2

Table 2 Allelic Diversity (He) of Plasmodium falciparum isolates by microsatellite loci.

To assess selection, LD measured as a standardized association index I_A^S between multiple P. falciparum loci in the study isolates revealed significant LD (I_A^S = 0.2865, P=0.02 and I_A^S = 0.3961, P=0.04 for pre- and post-treatment isolates respectively by Monte Carlo simulation method) around the neutral microsatellite loci.

Genetic analysis of Pfkelch-13 and coronin mutations

Sequence analysis of the Pfcoronin peculiar to the isolate of reduced artemisinin sensitivity, confirmed by microsatellite analysis, in this study revealed the earlier reported P76S mutation (http://www.malariagen.net) and two new (I68G and L173F) (Additional file, (S5)).

Previously reported coronin mutations (R100K/E107V) with demonstrated association with artemisinin resistance, and the Pfk13ART-resistance mutations (P574L/F446I/N458Y/Y493H/I543T/R539T/M476I/P553L/R561H/C580Y) were not detected. The Pfcoronin gene sequences (on Days 0,3, 7 and 14) of the isolate showing reduced sensitivity to AL in this study have been deposited in the GenBank database of National Centre for Biotechnological Information (https://www.ncbi.nlm.nih.gov/) with accession numbers MZ818700, OR344933, OR344934 and OR344935.

The dendrogram with the pfcoronin sequences of this isolate with suspected in vivo artemisinin insensitivity and those of different Plasmodium isolates of P. falciparum strains and other species showed clustering of the isolate with Pf3D7 (PF3D7_1246200),7G8 (Pf7G8-2_000400400), PfGB4_120056400, Dd2 (PfDd2_120056400), PfHB3_120056000, P. knowlesi (PfKH01_120057300) and PfNF54_120055000 sequences (Figure 5). All other six isolates, including those earlier suspected by allelic marker genotyping as likely recrudescence, showed no variance from the wild type Pfcoronin allele on Days 0 and Day of parasitaemia following AL administration.

Figure 5

Figure 5 Pfcoronin genetic relatedness. The evolutionary history was inferred using the Neighbor-Joining method (26). The optimal tree with the sum of branch length = 47.00125286 is shown. The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic tree. The evolutionary distances were computed using the Maximum Composite Likelihood method and are in the units of the number of base substitutions per site. The analysis involved 6 reference nucleotide sequences and the suspected isolate sequence (Isolate 7). All positions containing gaps and missing data were eliminated. There were a total of 434 positions in the final dataset. Evolutionary analyses were conducted in MEGA7 (24).

Analysis of the effects of these novel single nucleotide variants on protein stability and function of Pfcoronin showed that only one of the SNPs had a destabilizing effect (ΔΔG= - 0.). The remaining SNPs had positive ΔΔG values (Table 3).

Table 3

Table 3 Protein stability.

Drug resistance typing

HRM typing of drug resistance associated markers for pre- and post-treatment parasite genotyping showed that almost all the samples had the drug-resistance haplotypes 108_N/T (92.86%), 59_R (100%) and 51_I (%) in the Pfdhfr codons, however, only two isolates carried the drug resistance mutant allele I164L (14.29%). The Pfdhps 613T and 581G mutations were present in 50% and 7.14% of the parasite isolates, respectively. Pfmdr1 86Y and 184F mutations associated with reduced parasite sensitivity to lumefantrine were observed in 71.42% and 65.29% respectively, in the isolates.

Two isolates were observed to exhibit a quintuple Pfdhfr/Pfdhps haplotypes (108_T/N/51_I/164_L/59_R/581_G) in addition to Pfmdr1 double haplotype (86_Y/184_F) (Table 4). One of the isolates with this combined septuple haplotype showed parasitaemia post treatment and genotype features depicting recrudescence. All samples had the Pfcrt 76T drug resistance allele.

Table 4

Table 4 Antimalarial drug resistance target typing of pre- and post-treatment isolates.

Discussion

Antimalarial drug resistance threatens to continue eroding the traction gained by global malaria control and elimination efforts over the last decade. Its spread and reduced efficacy to the current ACTs will have a significant global health impact with potentially more devastating effect in Nigeria and other African countries with a disproportionately high burden of malaria morbidity and mortality.

This study, conducted in Lagos, South-west Nigeria, characterized P. falciparum isolates with suspected tolerance to Artermether-Lumefantrine following a 28-day in vivo TES. The goal was to investigate the role of parasite molecular mediators of reduced in vivo ART efficacy of AL against P. falciparum parasites in Nigeria. After a 3-day AL administration and 28-day follow-up, we observed P. falciparum recrudescence in a single clinical isolate among seven different subjects showing post treatment parasitaemia. Three cases of therapeutic failure of AL were reported before in Benin, Nigeria, a South-South city located about 321 km from Lagos, the site of the current study (Ebohon et al., 2019). Lagos is cosmopolitan, with significant in-ward urban migration that may bring in such parasites. This report and others in Africa call for more vigilance against ACT resistance in Africa, where Pfkelch-13 and other non-Kelch mediators of artemisinin tolerance are increasingly being reported (Normile, 2021).

Parasite DNA was detected in 27% of cases post-ACT administration. These could be residual DNA, or persistent asexual stages, that could be indicative of treatment tolerance and therefore should be further investigated as early indication of suspected ART-tolerant strains of P. falciparum populations from Nigeria. This is consistent with the report by Roth et al. (2018), using qPCR approach to monitor persistence of parasites in patients’ blood after drug administration. In this present study, recrudescent parasitaemia was confirmed only in a single infection, the implication of this is that, given the relatively small total number of participants followed up, parasites potential to tolerate ACT in Lagos and metropolis may be on the increase. In this setting, self-medication is prevalent, sub-optimal blood concentrations of these antimalarial drugs usually result in drug-tolerant, mostly asymptomatic, submicroscopic parasitaemia.

Molecular diagnostic techniques are more sensitive in detecting low levels of parasitemia. Though they are cumbersome, their sensitivity and cost-effectiveness, and deployment to detect viable parasites allows for application in monitoring antimalarial drug treatment. All four techniques used in this study showed reduction in post-treatment parasite DNA in blood samples, with the most sensitive being TARE-2 qPCR. Previous reports had shown TARE-2 to be less sensitive than other methods such as var-ATS in detecting low levels of parasitemia (Haanshuus et al., 2019). Moreover, TARE-2, a SYBR green based real-time PCR method, is less costly, in comparison with the Taqman var-ATS method. Analysis in the current study revealed that TARE-2, a multi-copy parasite gene, is equally as sensitive as the ultrasensitive var-ATS diagnostic marker. The application of this method in field settings may therefore need further investigation to maximize the benefits of its sensitivity and cost effectiveness in resource limited settings.

Further analysis based on twelve P. falciparum neutral microsatellite loci, revealed only one of the seven suspected post treatment infections could be classified as recrudescence. The remaining six were new or superinfection parasite isolates appearing in the peripheral blood within 28 days of ACT use. This implies that, although, P. falciparum parasites with reduced ART sensitivity may currently be few in Nigeria, they exist, and emerging.

Unexpectedly, msp2 genotypes did not show multi-clonality in the samples. Though Nigeria is a high transmission setting, where multiclonality is expected, the cases here were recruited in a semi urban setting, where transmission is relatively lower and could be the reason for the low complexity of infections. P. falciparum deploys several mechanisms to evade drugs, including dormancy against artemisinin derivatives, where a small sub-population of asexual parasites stop growing and dividing for days or weeks following drug exposure (Maiga et al., 2021). In general, ART resistance reflects an increased propensity for dormancy, but it is not clear whether very high efficacy of ACT outside areas of ART resistance suggests that dormant forms (or more likely these parasites when they wake) do not survive the residual concentrations of partner drugs (AL). This could be the case in Africa, where despite use of ACTs for over a decade, resistance to ART is not yet common. In this study, about 86% of cases with persistent parasite DNA (the suspected ACT tolerant isolates) could be classified as reinfection and this was within the half-life of Lumefantrine, the partner drug with Artemether in AL. Hence, they could in addition be tolerant to Lumefantrine.

Tolerance to ART partner drugs such as Mefloquine, Piperaquine and Lumefantrine are well known. Except in the case of Piperaquine in South East Asia, this has not been associated with clinical failure of ACTs (van der Pluijm et al., 2019; Maiga et al., 2021). Tolerance to Lumefantrine in Africa will affect the efficacy of AL, the most common ACT in Nigeria and Africa. It is also known that Lumefantrine selects for wild type variants of markers in Pfcrt (K76T) and Pfmdr1 (N86Y) that are associated with Chloroquine resistance (Bhagwat and Aravind, 2007; Adamu et al., 2020). The only isolates in suspected failure to AL carried the mutant variants at these markers. Hence, the potential failure in response to treatment may not be related to Lumefantrine tolerance but rather to patient factors or the most unlikely insensitivity to artemether.

Several other known drug resistance-associated mutations, pfdhfr/pfdhps/pfmdr1 (108_T/N/51_I/164_L/59_R/581_G/86_Y/184_F) (Daniels et al., 2012), were observed in the isolates with persistent parasite DNA. The drug resistance-associated haplotype pfdhfr/pfdhps/pfmdr1 affects the efficacy of several antimalarial drugs. As most of the isolates carried the mutant genotypes, this could have facilitated re-infection within the 28 days post AL administration.

The study found significant LD (nonrandom association between loci) around the neutral microsatellite loci, This finding is an indication that specific alleles or haplotypes of relevant genes are prevalent in this population, and might have expanded in the population. This implies a fitness advantage under the present antimalarial drug pressures. This may portend undesirable consequences on ART tolerance. Although, none of the validated mutations associated with ART resistance, with respect to pfk13, was detected, monitoring for these and mutations in other markers, especially Pfcoronin, is important to mitigate against resistance.

No Pfkelch-13 ART resistance-associated variants were found in any of the persistent parasitemia isolates from this study. However, three non-synonymous Pfcoronin mutations were observed in the single infection suspected to be recrudescence and tolerant to AL. Only one of the variants had been described before, while two others were novel. Pfcoronin is an actin binding protein and three mutant forms selected on the background of Senegalese isolates show increased survival against dihydroartemisinin (DHA) in in vitro selection and CRISPR-Cas9 genetic editing experiments (Demas et al., 2018).

Though the variants found here differ, they are within the WD domain and therefore could alter the function of the protein and increase ART tolerance. The implication of this is predicated on the potential of Nigerian P. falciparum population for high gene flow rate, and circulation of resistance-associated SNVs. From structural models of the mutant forms of the protein, one of the variants (L173F) had a significant effect on the protein structure. More molecular and therapeutic response analysis from this population, as well as host and parasite factors underlying reduced ACT efficacy are urgently needed in the site studied here and across Nigeria. This is important as malaria is highly prevalent in Nigeria, and access to drugs in the informal sector is easy with resultant negative effects on sustained drug efficacy.

ACTs are the only WHO approved effective first-line drug against uncomplicated malaria. However, resistance to ART may be emerging or spreading as in the case of chloroquine (Haanshuus et al., 2019; Maiga et al., 2021). Although the WHO had encouraged all endemic countries to actively conduct ACT resistance surveillance, the will, resources and capacity to actualize this may be non-existent in most endemic African countries. The situation is currently worsened by the COVID-19 pandemic, with potential unclear impact on treatment outcomes and antimalarial drug metabolism and efficacy. A major aim of the global technical strategy (GTS) for malaria for a reduction in malaria case incidence and mortality rate of 75% by 2025 and 90% by 2030, from the 2015 baseline (WHO, 2023), may therefore be defeated.

Two non-synonymous nucleotide variants, with resultant codon mutations, were observed in the isolate implicated in the recrudescence infection in this study. Apart from the P76S variant, the. other two are new variants. Structure-based protein stability analysis conducted in relation to function, revealed a general stabilizing effect (Chen et al., 2020), but the L173F SNV had a destabilizing influence on the actin-binding ability of Pfcoronin. Whether this has an overall relationship with the parasite’s sensitivity to drug or not is currently unclear.

Although, Pfcoronin has structural similarity with Pfkelch-13, it is functionally distinct. Its biological function outside of F-actin organization remains unconfirmed. In vitro, pfcoronin gene mutations knockin has shown the effects of polymorphisms on the functional role of Pfcoronin in parasite ART tolerance. Pfcoronin implication in antimalarial drug resistance implies a catastrophic consequence on malaria eradication globally. This will be more debilitating in Nigeria where 27% of the global malaria burden resides.

Phylogenetic analysis of the AL-insensitive isolate from this study showed clustering and evolutionary relationship with known strains of P. falciparum including the Brazilian 7G8 strain. Studies focused on parasite genomic mediators of in vivo ART tolerance have only been minimally carried out or reported in Nigeria. To conclude, this current study confirmed that Nigerian P. falciparum populations are unique and complex, and reported novel SNPs in Pfcoronin as a possible kelch13-independent ART-resistance mechanism. Findings from this study would inform national policy on health research for attention focused on both known and novel ACT resistance factors. These findings suggest to relevant agencies in the country, and other endemic countries, to put in place necessary intervention and control measures to stop the spread of artemisinin or ACT tolerance among populations in the country to fast track malaria elimination.

Further studies with larger sample size are required to elucidate complex parasite factors driving reduced sensitivity to ART in Nigeria. Although efforts are ongoing to explore novel targets for discovery of new antimalarials (Komatsuya et al., 2013; Suzuki et al., 2015; Hartuti et al., 2018), the present report corroborates the need for routine surveillance for drug resistance signatures and patterns in endemic regions.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

Ethics statement

The studies involving humans were approved by The Nigerian Institute of Medical Research Institutional Ethics review Board. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants’ legal guardians/next of kin. Written informed consent was obtained from the individual(s), and minor(s)’ legal guardian/next of kin, for the publication of any potentially identifiable images or data included in this article.

Author contributions

OAj: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Validation, Writing – original draft, Writing – review & editing. YO: Investigation, Supervision, Writing – review & editing. EO: Data curation, Formal analysis, Investigation, Writing – review & editing. MO: Data curation, Writing – review & editing. BI: Supervision, Writing – review & editing. IN: Formal analysis, Investigation, Methodology, Writing – review & editing. CN: Formal analysis, Investigation, Writing – review & editing. OA: Data curation, Investigation, Project administration, Writing – review & editing. SC: Writing – review & editing. JO: Writing – review & editing. EG: Formal analysis, Writing – review & editing. EB: Investigation, Supervision, Writing – review & editing. AA-N: Funding acquisition, Investigation, Methodology, Project administration, Supervision, Writing – original draft, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by a seed fund from the Medical Research council, The Gambia at the London School of Hygiene and Tropical Medicine (MRCG-LSHTM) -West African Network for TB, Aids and Malaria (WANETAM). We appreciate the African Research Excellence funds (AREF: AREF-318-AJIB-F-C0885) for additional Training Funds which further supported this work. EB is a recipient of the Emerging Global Leader (K43) Award and supported by FIC/NIH under Award Number K43TW012015. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Acknowledgments

We appreciate all participants and staff at Ijede General Hospital, Ikorodu, Lagos, Nigeria that took part in the study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcimb.2024.1366563/full#supplementary-material

References

Adams, J., Kelso, R., Cooley, L. (2000). The kelch repeat superfamily of proteins: Propellers of cell function. Trends Cell Biol. 10, 17–24. doi: 10.1016/S0962-8924(99)01673-6

PubMed Abstract | CrossRef Full Text | Google Scholar

Adamu, A., Jada, M. S., Haruna, H. M. S., Yakubu, B. O., Ibrahim, M. A., Balogun, E. O., et al. (2020). Plasmodium falciparum multidrug resistance gene-1 polymorphisms in Northern Nigeria: implications for the continued use of artemether-lumefantrine in the region. Malaria J. 19, 1–10. doi: 10.1186/s12936-020-03506-z

CrossRef Full Text | Google Scholar

Ajibaye, O., Osuntoki, A. A., Balogun, E. O., Olukosi, Y. A., Iwalokun, B. A., Oyebola, K. M., et al. (2020). Genetic polymorphisms in malaria vaccine candidate Plasmodium falciparum reticulocyte-binding protein homologue-5 among populations in Lagos, Nigeria. Malar J. 19, 6. doi: 10.1186/s12936-019-3096-0

PubMed Abstract | CrossRef Full Text | Google Scholar

Anderson, T. J. C., Haubold, B., Williams, J. T., Estrada-Franco, J. G., Richardson, L., Mollinedo, R., et al. (2006). Microsatellite markers reveal a spectrum of population structures in the malaria parasite plasmodium falciparum. Mol. Biol. Evol. 17, 1467–1482. doi: 10.1093/oxfordjournals.molbev.a026247

CrossRef Full Text | Google Scholar

Auburn, S., Campino, S., Clark, T. G., Djimde, A. A., Zongo, I., Pinches, R. (2011). An effective method to purify plasmodium falciparum DNA directly from clinical blood samples for whole genome high-throughput sequencing. PloS One 6, 1–8. doi: 10.1371/journal.pone.0022213

CrossRef Full Text | Google Scholar

Bhagwat, M., Aravind, L. (2007). PSI-BLAST tutorial. Methods Mol. Biol. (Clifton N.J.) 395, 177–186. doi: 10.1007/978-1-59745-514-5_10

CrossRef Full Text | Google Scholar

Chen, Y., Lu, H., Zhang, N., Zhu, Z., Wang, S., Li, M. (2020). PremPS: Predicting the impact of missense mutations on protein stability. PloS Comput. Biol. 16, 1–22. doi: 10.1371/journal.pcbi.1008543

CrossRef Full Text | Google Scholar

Conrad, M. D., Rosenthal, P. J. (2019). Antimalarial drug resistance in Africa: the calm before the storm? Lancet Infect. Dis. 19 (10), e338–e351. doi: 10.1016/S1473-3099(19)30261-0

PubMed Abstract | CrossRef Full Text | Google Scholar

Daniels, R., Ndiaye, D., Wall, M., McKinney, J., Séne, P. D., Sabeti, P. C., et al. (2012). Rapid, field-deployable method for genotyping and discovery of single-nucleotide polymorphisms associated with drug resistance in Plasmodium falciparum. Antimicrobial. Agents chemother. 56, 2976–2986. doi: 10.1128/AAC.05737-11

CrossRef Full Text | Google Scholar

Demas, A. R., Sharma, A. I., Wong, W., Early, A. M., Redmond, S., Bopp, S., et al. (2018). Mutations in Plasmodium falciparum actin-binding protein coronin confer reduced artemisinin susceptibility. Proc. Natl. Acad. Sci. U.S.A. 115 (50), 12799–12804. doi: 10.1073/pnas.1812317115

PubMed Abstract | CrossRef Full Text | Google Scholar

Desjardins, P., Conklin, D. (2010). NanoDrop microvolume quantitation of nucleic acids. J. visual. exper.: JoVE 45), 2565. doi: 10.3791/2565

CrossRef Full Text | Google Scholar

Druml, T., Curik, I., Baumung, R., Aberle, K., Distl, O., Sölkner, J. (2006). Individual-based assessment of population structure and admixture in Austrian, Croatian and German draught horses. Hered. (Edinb); 98, 114–122. doi: 10.1038/sj.hdy.6800910

CrossRef Full Text | Google Scholar

Ebohon, O., Irabor, F., Ebohon, L. O., Omoregie, E. S. (2019). Therapeutic failure after regimen with artemether-lumefantrine combination therapy: a report of three cases in Benin City, Nigeria. J. Braz. Soc. Trop. Med. 52. doi: 10.1590/0037-8682-0163-2019

CrossRef Full Text | Google Scholar

Haanshuus, C. G., Mørch, K., Blomberg, B., Strøm, G. E. A., Langeland, N., Hanevik, K. (2019). Assessment of malaria real-time PCR methods and application with focus on low-level parasitaemia. PloS One 14, e0218982. doi: 10.1371/journal.pone.0218982

PubMed Abstract | CrossRef Full Text | Google Scholar

Hartuti, E. D., Inaoka, D. K., Komatsuya, K., Miyazaki, Y., Miller, R. J., Xinying, W., et al. (2018). Biochemical studies of membrane bound Plasmodium falciparum mitochondrial L-malate: quinone oxidoreductase, a potential drug target. Biochim. Biophys. Acta (BBA)-Bioenerg. 1859, 191–200. doi: 10.1016/j.bbabio.2017.12.004

CrossRef Full Text | Google Scholar

Haubold, B., Hudson, R. R. (2000). LIAN 3.0: detecting linkage disequilibrium in multilocus data. Link. Anal. Bioinformatics; 16, 847–848. doi: 10.1093/bioinformatics/16.9.847

CrossRef Full Text | Google Scholar

Henrici, R. C., van, Schalkwyk, D. A., Sutherland, C. J. (2019). Modification of pfap2μ and pfubp1 Markedly Reduces Ring-Stage Susceptibility of Plasmodium falciparum to Artemisinin In Vitro. Antimicrobial. Agents And Chemother. 64, e01542–e01519. doi: 10.1128/AAC.01542-19

CrossRef Full Text | Google Scholar

Hofmann, N., Mwingira, F., Shekalaghe, S., Robinson, L. J., Mueller, I., Felger, I. (2015). Ultra-sensitive detection of plasmodium falciparum by amplification of multi-copy subtelomeric targets. PloS Med. 12 (3), 1–21. doi: 10.1371/journal.pmed.1001788

CrossRef Full Text | Google Scholar

Ikegbunam, M., Ojo, J. A., Kokou, K., Morikwe, U., Nworu, C., Uba, C., et al. (2021). Absence of Plasmodium falciparum artemisinin resistance gene mutations eleven years after the adoption of artemisinin-based combination therapy in Nigeria. Malar J. 20, 434. doi: 10.1186/s12936-021-03968-9

PubMed Abstract | CrossRef Full Text | Google Scholar

Komatsuya, K., Hata, M., Balogun, E. O., Hikosaka, K., Suzuki, S., Takahashi, K., et al. (2013). Synergy of ferrous ion on 5-aminolevulinic acid-mediated growth inhibition of Plasmodium falciparum. J. Biochem. 154, 501–504. doi: 10.1093/jb/mvt096

PubMed Abstract | CrossRef Full Text | Google Scholar

Kumar, S., Stecher, G., Tamura, K. (2016). MEGA7: Molecular Evolutionary Genetics Analysis version 7.0 for bigger datasets. Mol. Biol. Evol. 33, 1870–1874. doi: 10.1093/molbev/msw054

PubMed Abstract | CrossRef Full Text | Google Scholar

Maiga, H., Grivoyannis, A., Sagara, I., Traore, K., Traore, O. B., Tolo, Y., et al. (2021). Selection of pfcrt K76 and pfmdr1 N86 Coding Alleles after Uncomplicated Malaria Treatment by Artemether-Lumefantrine in Mali. Int. J. Mol. Sci. 22, 6057. doi: 10.3390/ijms22116057

PubMed Abstract | CrossRef Full Text | Google Scholar

Murray, L., Mobegi, V. A., Duffy, C. W. (2016). Microsatellite genotyping and genome-wide single nucleotide polymorphism-based indices of Plasmodium falciparum diversity within clinical infections. Malar J. 15, 275. doi: 10.1186/s12936-016-1324-4

PubMed Abstract | CrossRef Full Text | Google Scholar

Normile, D. (2021). Threat of drug-resistant malaria looms in Africa. Science 373 (6562), 1427 doi: 10.1126/science.acx9160

PubMed Abstract | CrossRef Full Text | Google Scholar

Oladipo, H. J., Tajudeen, Y. A., Oladunjoye, I. O., Yusuff, S. I., Yusuf, R. O., Oluwaseyi, E. M., et al. (2022). Increasing challenges of malaria control in sub-Saharan Africa: Priorities for public health research and policymakers. Ann. Med. Surg. (Lond). 81, 1–6. doi: 10.1016/j.amsu.2022.104366

CrossRef Full Text | Google Scholar

Peakall, R., Smouse, P. E. (2006). genalex 6: genetic analysis in excel. population genetic software for teaching and research. Mol. Ecol. Notes. 6, 288–295. doi: 10.1111/j.1471-8286.2005.01155.x

CrossRef Full Text | Google Scholar

Roth, J. M., Sawa, P., Omweri, G., Makio, N., Osoti, V., de Jong, M. D., et al. (2018). Molecular Detection of Residual Parasitemia after Pyronaridine-Artesunate or Artemether-Lumefantrine Treatment of Uncomplicated Plasmodium falciparum Malaria in Kenyan Children. Am. J. Trop. Med. Hyg. 99, 970–977. doi: 10.4269/ajtmh.18-0233

PubMed Abstract | CrossRef Full Text | Google Scholar

Rutledge, G., Böhme, U., Sanders, M. (2017). Plasmodium malariae and P. ovale genomes provide insights into malaria parasite evolution. Nature 542, 101–104. doi: 10.1038/nature2103818

PubMed Abstract | CrossRef Full Text | Google Scholar

Saitou, N., Nei, M. (1987). The neighbor-joining method: A new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4, 406–425. doi: 10.1093/oxfordjournals.molbev.a040454

PubMed Abstract | CrossRef Full Text | Google Scholar

Selvaraj, P., Wenger, E. A., Gerardin, J. (2018). Seasonality and heterogeneity of malaria transmission determine success of interventions in high-endemic settings: a modeling study. BMC Infect. Dis; 18, 413. doi: 10.1186/s12879-018-3319-y

PubMed Abstract | CrossRef Full Text | Google Scholar

Sharma, A. I., Shin, S. H., Bopp, S. (2020). Genetic background and Pfkelch-13 affect artemisinin susceptibility of PfCoronin mutants in Plasmodium falciparum. PloS Genet. 16, 1–16. doi: 10.1371/journal.pgen.1009266

CrossRef Full Text | Google Scholar

Snounou, G. (2002). Genotyping of Plasmodium spp. nested PCR. Methods Mol. Med. 72, 103–116. doi: 10.1385/1-59259-271-6:103

PubMed Abstract | CrossRef Full Text | Google Scholar

Snounou, G., Beck, H. P. (2002). The use of PCR genotyping in the assessment of recrudescence or rein-fection after antimalarial drug treatment. Parasitol. Today 14, 462–467. doi: 10.1016/s0169-4758(98)01340-4

CrossRef Full Text | Google Scholar

Stokes, B. H., Dhingra, S. K., Rubiano, K., Mok, S., Straimer, J., Gnädig, N. F., et al. (2021). Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness. Elife 10, e66277. doi: 10.7554/eLife.66277.sa2

PubMed Abstract | CrossRef Full Text | Google Scholar

Suzuki, S., Hikosaka, K., Balogun, E. O., Komatsuya, K., Niikura, M., Kobayashi, F., et al. (2015). In vivo curative and protective potential of orally administered 5-aminolevulinic acid plus ferrous ion against malaria. Antimicrobial. Agents Chemother. 59, 6960–6967. doi: 10.1128/AAC.01910-15

CrossRef Full Text | Google Scholar

Tamura, K., Nei, M., Kumar, S. (2004). Prospects for inferring very large phylogenies by using the neighbor-joining method. Proc. Natl. Acad. Sci. (USA) 101, 11030–11035. doi: 10.1073/pnas.0404206101

CrossRef Full Text | Google Scholar

Taylor, A. R., Watson, J. A., Chu, C. S., Puaprasert, K., Duanguppama, J., Day, N. P. J., et al. (2018). Estimating the probable cause of recurrence in Plasmodium vivax malaria: relapse, reinfection or recrudescence? BioRxiv. 81, 1–6. doi: 10.1101/505594

CrossRef Full Text | Google Scholar

Tiwari, K. L., Jadhav, S. K., Gupta, S. (2012). Modified CTAB technique for isolation of DNA from some medicinal plants. Res. J. Med. 6, 65–73. Available at: https://scialert.net/abstract/?doi=rjmp.2012.65.73.

Google Scholar

van der Pluijm, R. W., Imwong, M., Chau, N. H., Hoa, N., Thuy-Nhien, N. T., Thanh, N. V., et al. (2019). Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infect. Dis. 19, 952–961. doi: 10.1016/S1473-3099(19)30391-3

PubMed Abstract | CrossRef Full Text | Google Scholar

Venkatesan, M., Amaratunga, C., Campino, S., Auburn, S., Koch, O., Lim, P., et al. (2012). Using CF11 cellulose columns to inexpensively and effectively remove human DNA from Plasmodium falciparum-infected whole blood samples. Malar J. 10, 11:41. doi: 10.1186/1475-2875-11-41

CrossRef Full Text | Google Scholar

White, N. J. (2004). Antimalarial drug resistance. J. Clin. Invest. 113, 1084–1092. doi: 10.1172/JCI21682

PubMed Abstract | CrossRef Full Text | Google Scholar

WHO (2023). World malaria report (Geneva: World Health Organization). Licence: CC BY-NC-SA 3.0 IGO.

Google Scholar

World Health Organization (2022). Global genomic surveillance strategy for pathogens with pandemic and epidemic potential 2022–2032.

Google Scholar

WWARN (2019). K13 Genotype-Phenotype Study Group. Association of mutations in the Plasmodium falciparum Kelc-13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatments—a WWARN individual patient data meta-analysis. BMC Med. 17 (1), 1–20. doi: 10.1186/s12916-018-1207-3

PubMed Abstract | CrossRef Full Text | Google Scholar

Xavier, C. P., Eichinger, L., Fernandez, M. P., Morgan, R. O., Clemen, C. S. (2008). Evolutionary and functional diversity of coronin proteins. Subcell Biochem. 48, 98–109. doi: 10.1007/978-0-387-09595-0_9

PubMed Abstract | CrossRef Full Text | Google Scholar

Yobi, D. M., Kayiba, N. K., Mvumbi, D. M., Boreux, R., Bontems, S., Kabututu, P. Z., et al. (2020). The lack of K13-propeller mutations associated with artemisinin resistance in Plasmodium falciparum in Democratic Republic of Congo (DRC). PloS One 15, 1–9. doi: 10.1371/journal.pone.0237791

CrossRef Full Text | Google Scholar